Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

KWTRP has launched a dataset of comprehensive public health facilities from 50 countries in sub- Saharan Africa. This new dataset locates health facilities in relation to the communities they are intended to serve, to help ensure that services are accessible to the right populations and that no one is geographically marginalized from essential services. This is critical for attainment of Sustainable Development Goal 3 on good health and wellbeing.

Africa Map

The KEMRI Wellcome Trust Research Program has launched a dataset of comprehensive public health facilities from 50 countries and islands in sub-Saharan Africa. Linking health facilities to populations has traditionally been based on a health facility per/capita basis, often ignoring the geographic, social and economic drivers of health facility distribution. This new dataset is important because, it locates health facilities in relation to the communities they are intended to serve. The location of health facilities forms a key cornerstone for health system planning, particularly by ensuring that the right services are accessible to the right populations and that no one is geographically marginalized from essential services. This is critical for attainment of Sustainable Development Goal 3 on good health and wellbeing.

This dataset contains information on 98,745 public health facilities managed by governments, local authorities, faith-based organisations and non-governmental organisation that offer health services to the general population. This is an important geo-coded database that should be available in the public domain, and the first comprehensive spatial inventory of public health facilities for sub Saharan Africa.

The lead investigator and also Head of Population Health Unit at KEMRI-Wellcome Trust Research Programme Dr. Emelda Okiro, states “the database will be useful across numerous domains for evaluating public health sector service delivery and optimizing health care to evaluating the emergence of epidemic pathogens and will be an invaluable resource tool for governments in the quest to provide Universal Health Coverage- Defining and planning for universal equity in access to health services demands better data on the location of both services and populations they are intended to serve.”

In the creation of this dataset, country-specific public health facility databases were developed through a careful documentation, validation and curation process of data assembly from a variety of sources.
The comprehensive master facility list is freely available through the figshare repository and through the World Health Organization’s Global Malaria Programme

The data set available on the WHO platform will be continuously updated through further in-depth validation and collaborations with individual countries. The research team behind this project recognises that the dataset is incomplete and will change overtime. As such, they encourage readers to alert them via email on additional and/or newly available data. The information provided will be vetted and included into the data set if found appropriate.

Read more: Maina, J. et al. A spatial database of health facilities managed by the public health sector in sub Saharan Africa. figshare (2019)

Africa Map

The 50 countries included in this data set are: Burundi, Central African Republic, Ghana, Guinea, Liberia, Malawi, Mali, Mozambique, Namibia, Nigeria, Rwanda, Sierra Leone, Somalia, South Africa, South Sudan, Tanzania, Zimbabwe, Botswana, Chad, Comoros, Gambia, Kenya, Lesotho, Senegal, Seychelles, Togo, Uganda Zambia, Benin, Burkina Faso, Cameroon, Cape Verde, Cote d’Ivoire, Djibouti, Equatorial Guinea, Eritrea, eSwatini, Ethiopia, Gabon, Guinea-Bissau, Mauritania, Mauritius, Niger, São Tomé & Príncipe, Zanzibar Angola, Congo, Democratic Republic of Congo, Madagascar and Sudan

Similar stories

Simple blood tests may help improve malaria diagnosis in clinical studies

About one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.

OUCRU scientists identify combination of biological markers associated with severe dengue

Nguyen Lam Vuong, Sophie Yacoub & colleagues have identified a combination of biological markers in patients with dengue that could predict whether they go on to develop moderate to severe disease. Biomarkers are used to identify the state or risk of a disease in patients; these findings could aid the development of biomarker panels for clinical use and help improve triage and risk prediction in patients with dengue.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with COVID-19. Patients with COVID-19 are at increased risk of blood clots forming in their blood vessels, particularly in the lungs. Between November 2020 and March 2021, the RECOVERY trial included nearly 15,000 patients hospitalised with COVID-19 in an assessment of the effects of aspirin, which is widely used to reduce blood clotting in other diseases. There was no significant difference in the primary endpoint of 28-day mortality

The COVID-19 International Modelling Consortium (CoMo Consortium) enters a new phase

Created in March 2020 to assist policymakers to make use of existing evidence in mathematical and epidemiological models to inform strategies for minimising the impact of COVID-19, the CoMo Consortium brings together mathematical modellers, epidemiologists, health economists and public health experts from more than 40 countries across Africa, Asia and South and North America.